Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice

Life Sciences

Volumn 92, Issue 12, 2013, Pages 708-718

  Sann, Holger ^a   Erichsen, Jasmin Von ^a   Hessmann, Manuela ^a   Pahl, Andreas ^a   Hoffmeyer, Angelika ^b  

^a IPAS   (United States)

^b Nycomed: A Takeda Company   (Germany)

Author keywords

5 ASA; 6 Thioguanine; Colitis; Combination therapy; Cyclosporine A; Dextran sodium sulphate; EP4 agonist; IBD

Indexed keywords

AGN 205203; BUDESONIDE; CYCLOSPORIN A; DEXTRAN SULFATE; MESALAZINE; MYELOPEROXIDASE; OLSALAZINE; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SANDIMMUN OPTORAL; SERUM AMYLOID A; TIOGUANINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; INFLAMMATION; INTESTINAL BLEEDING; MOUSE; NONHUMAN; WEIGHT REDUCTION;

AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS; COLON; CYCLOSPORINE; DEXTRAN SULFATE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; MICE; MICE, INBRED BALB C; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; THIOGUANINE;

MUS;

EID: 84875209888     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.01.028     Document Type: Article

References (40)

1. L.G. Axelsson, E. Landström, and A.C. Bylund-Fellenius Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine Aliment Pharmacol Ther 12 1998 925 934
2. M. Banić, B. Anić, T. Brkić, N. Ljubicić, S. Plesko, and C. Dohoczky Effect of cyclosporine in a murine model of experimental colitis Dig Dis Sci 47 2002 1362 1368
3. S.C. Bischoff, R. Mailer, O. Pabst, G. Weier, W. Sedlik, and Z. Li Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice Am J Physiol 296 2009 G685 G695
4. L. Chouchana, C. Narjoz, P. Beaune, M.A. Loriot, and X. Roblin Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease Aliment Pharmacol Ther 35 2012 15 36
5. S. Danese New therapies for inflammatory bowel disease: from the bench to the bedside Gut 61 2012 918 932
6. N. Diaz-Granados, K. Howe, J. Lu, and D.M. McKay Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity Am J Pathol 156 2000 2169 2177
7. A. Dignass, G. Van Assche, J.O. Lindsay, M. Lémann, J. Söderholm, and J.F. Colombel European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management J Crohns Colitis 4 2010 28 62
8. B. Egger, M. Bajaj-Elliott, T.T. MacDonald, R. Inglin, V.E. Eysselein, and M.W. Büchler Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency Digestion 62 2000 240 248
9. M. Fritsch Fredin, A. Vidal, H. Utkovic, Y.Y. Götlind, R. Willén, and L. Jansson The application and relevance of ex vivo culture systems for assessment of IBD treatment in murine models of colitis Pharmacol Res 58 2008 222 231
10. M. Graffner-Nordberg, M. Fyfe, R. Brattsand, B. Mellgård, and A. Hallberg Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model J Med Chem 46 2003 3455 3462
11. Y. Hayashi, K. Aoyagi, I. Morita, C. Yamamoto, and S. Sakisaka Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats Scand J Gastroenterol 44 2009 1323 1331
12. G.L. Jiang, A. Nieves, W.B. Im, D.W. Old, D.T. Dinh, and L. Wheeler The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration J Pharmacol Exp Ther 320 2007 22 28
13. G.L. Jiang, W.B. Im, Y. Donde, and L.A. Wheeler Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment J Pharmacol Exp Ther 335 2010 546 552
14. K. Kabashima, T. Saji, T. Murata, M. Nagamachi, T. Matsuoka, and E. Segi The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut J Clin Invest 109 2002 883 893
15. I. Koboziev, F. Karlsson, S. Zhang, and M.B. Grisham Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies Inflamm Bowel Dis 17 2011 1229 1245
16. G. Kojouharoff, W. Hans, F. Obermeier, D.N. Männel, T. Andus, and J. Schölmerich Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice Clin Exp Immunol 107 1997 353 358
17. M. Kverka, P. Rossmann, H. Tlaskalova-Hogenova, K. Klimesova, B. Jharap, and N.K. de Boer Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis BMC Gastroenterol 11 2011 47
18. F.S. Laroux, H.H. Norris, J. Houghton, K.P. Pavlick, S. Bharwani, and D.M. Merrill Regulation of chronic colitis in athymic nu/nu (nude) mice Int Immunol 16 2004 77 89
19. M.C. L'Heureux, and P.L. Brubaker Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis J Pharmacol Exp Ther 306 2003 347 354
20. F. Loher, K. Schmall, P. Freytag, N. Landauer, R. Hallwachs, and C. Bauer The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice J Pharmacol Exp Ther 305 2003 549 556
21. M. Mähler, I.J. Bristol, E.H. Leiter, A.E. Workman, E.H. Birkenmeier, and C.O. Elson Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis Am J Physiol 274 1998 G544 G551
22. L.W. Maines, L.R. Fitzpatrick, K.J. French, Y. Zhuang, Z. Xia, and S.N. Keller Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase Dig Dis Sci 53 2008 997 1012
23. J.A. Marrero, K.A. Matkowskyj, K. Yung, G. Hecht, and R.V. Benya Dextran sulfate sodium-induced murine colitis activates NF-kappaB and increases galanin-1 receptor expression Am J Physiol 278 2000 G797 G804
24. J.R. Maxwell, W.A. Brown, C.L. Smith, F.R. Byrne, and J.L. Viney Methods of inducing inflammatory bowel disease in mice Curr Protoc Pharmacol 47 2009 5.58.1 5.58.37
25. J. Meier, and A. Sturm Current treatment of ulcerative colitis World J Gastroenterol 17 2011 3204 3212
26. S. Melgar, A. Karlsson, and E. Michaëlsson Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation Am J Physiol 288 2005 G1328 G1338
27. S. Melgar, L. Karlsson, E. Rehnström, A. Karlsson, H. Utkovic, and L. Jansson Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease Int Immunopharmacol 8 2008 836 844
28. S.N. Murthy, H.S. Cooper, H. Shim, R.S. Shah, S.A. Ibrahim, and D.J. Sedergran Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin Dig Dis Sci 38 1993 1722 1734
29. S. Murthy, N.S. Murthy, D. Coppola, and D.L. Wood The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis Inflamm Res 46 1997 224 233
30. H. Nakase, Y. Fujiyama, N. Oshitani, T. Oga, K. Nonomura, and T. Matsuoka Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial Inflamm Bowel Dis 16 2010 731 733
31. M. Noti, N. Corazza, C. Mueller, B. Berger, and T. Brunner TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis J Exp Med 207 2010 1057 1066
32. A.D. Olson, E.A. DelBuono, K.N. Bitar, and D.G. Remick Antiserum to tumor necrosis factor and failure to prevent murine colitis J Pediatr Gastroenterol Nutr 21 1995 410 418
33. P. Rafiee, C.P. Johnson, M.S. Li, H. Ogawa, J. Heidemann, and P.J. Fisher Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium J Biol Chem 277 2002 35605 35615
34. Y. Satoh, Y. Ishiguro, H. Sakuraba, S. Kawaguchi, H. Hiraga, and S. Fukuda Cyclosporine regulates intestinal epithelial apoptosis via TGF-beta-related signaling Am J Physiol 297 2009 G514 G519
35. A. Soriano-Izquierdo, M. Gironella, A. Massaguer, A. Salas, F. Gil, and J.M. Piqué Effect of cyclosporin A on cell adhesion molecules and leukocyte-endothelial cell interactions in experimental colitis Inflamm Bowel Dis 10 2004 789 800
36. M.E. van Meeteren, M.A. Meijssen, and F.J. Zijlstra The effect of dexamethasone treatment on murine colitis Scand J Gastroenterol 35 2000 517 521
37. T. Vowinkel, T.J. Kalogeris, M. Mori, C.F. Krieglstein, and D.N. Granger Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis Dig Dis Sci 49 2004 556 564
38. S. Wirtz, C. Neufert, B. Weigmann, and M.F. Neurath Chemically induced mouse models of intestinal inflammation Nat Protoc 2 2007 541 546
39. Y. Yan, V. Kolachala, G. Dalmasso, H. Nguyen, H. Laroui, and S.V. Sitaraman Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis PLoS One 4 2009 e6073
40. F.J. Zijlstra, I.M. Garrelds, A.P. van Dijk, and J.H. Wilson Experimental colitis in mice: effects of olsalazine on eicosanoid production in colonic tissue Agents Actions 1992 Spec Conference Issue:C76-8